Search Results
Search for other papers by W F Symmans in
Google Scholar
PubMed
Search for other papers by D J Fiterman in
Google Scholar
PubMed
Search for other papers by S K Anderson in
Google Scholar
PubMed
Search for other papers by M Ayers in
Google Scholar
PubMed
Search for other papers by R Rouzier in
Google Scholar
PubMed
Search for other papers by V Dunmire in
Google Scholar
PubMed
Search for other papers by J Stec in
Google Scholar
PubMed
Search for other papers by V Valero in
Google Scholar
PubMed
Search for other papers by N Sneige in
Google Scholar
PubMed
Search for other papers by C Albarracin in
Google Scholar
PubMed
Search for other papers by Y Wu in
Google Scholar
PubMed
Search for other papers by J S Ross in
Google Scholar
PubMed
Search for other papers by P Wagner in
Google Scholar
PubMed
Search for other papers by R L Theriault in
Google Scholar
PubMed
Search for other papers by B Arun in
Google Scholar
PubMed
Search for other papers by H Kuerer in
Google Scholar
PubMed
Search for other papers by K R Hess in
Google Scholar
PubMed
Search for other papers by W Zhang in
Google Scholar
PubMed
Search for other papers by G N Hortobagyi in
Google Scholar
PubMed
Search for other papers by L Pusztai in
Google Scholar
PubMed
), intermediate (2) or high (3)) according to the modified Black’s nuclear grading system, primary tumor stage (T1–T4), regional nodal stage (N0–N3), ER status (positive if ≥ 10%), and HER2 status (positive if FISH ratio of >2.0 or IHC 3 + and FISH unknown
Search for other papers by Catherine M Olsen in
Google Scholar
PubMed
Search for other papers by Christina M Nagle in
Google Scholar
PubMed
Search for other papers by David C Whiteman in
Google Scholar
PubMed
Search for other papers by Roberta Ness in
Google Scholar
PubMed
Search for other papers by Celeste Leigh Pearce in
Google Scholar
PubMed
Queensland Institute of Medical Research, School of Public Health, Department of Preventive Medicine, Department of Epidemiology and Biostatistics, Program in Epidemiology, Obstetrics and Gynecology Epidemiology Center, Peter MacCallum Cancer Centre, Department of Epidemiology and Public Health, Cancer Epidemiology Program, Division of Cancer Epidemiology, Department of Obstetrics and Gynecology, Department of Biomedical Sciences, Department of Obstetrics and Gynecology, Roswell Park Cancer Center, Virus, Gynecologic Clinic, Department of Health Sciences Research, Department of Community and Family Medicine, Robert Wood Johnson Medical School, School of Public Health, National Cancer Institute, Division of Genetics and Epidemiology, Department of Cancer Epidemiology and Prevention, Department of Epidemiology, Department of Gynaecological Oncology, Royal Brisbane Hospital, Locked Bag 2000, Brisbane, Queensland 4029, Australia
Search for other papers by Malcolm C Pike in
Google Scholar
PubMed
Search for other papers by Mary Anne Rossing in
Google Scholar
PubMed
Search for other papers by Kathryn L Terry in
Google Scholar
PubMed
Search for other papers by Anna H Wu in
Google Scholar
PubMed
Search for other papers by The Australian Cancer Study (Ovarian Cancer) in
Google Scholar
PubMed
Queensland Institute of Medical Research, School of Public Health, Department of Preventive Medicine, Department of Epidemiology and Biostatistics, Program in Epidemiology, Obstetrics and Gynecology Epidemiology Center, Peter MacCallum Cancer Centre, Department of Epidemiology and Public Health, Cancer Epidemiology Program, Division of Cancer Epidemiology, Department of Obstetrics and Gynecology, Department of Biomedical Sciences, Department of Obstetrics and Gynecology, Roswell Park Cancer Center, Virus, Gynecologic Clinic, Department of Health Sciences Research, Department of Community and Family Medicine, Robert Wood Johnson Medical School, School of Public Health, National Cancer Institute, Division of Genetics and Epidemiology, Department of Cancer Epidemiology and Prevention, Department of Epidemiology, Department of Gynaecological Oncology, Royal Brisbane Hospital, Locked Bag 2000, Brisbane, Queensland 4029, Australia
Search for other papers by Australian Ovarian Cancer Study Group in
Google Scholar
PubMed
Search for other papers by Harvey A Risch in
Google Scholar
PubMed
Search for other papers by Herbert Yu in
Google Scholar
PubMed
Search for other papers by Jennifer A Doherty in
Google Scholar
PubMed
Search for other papers by Jenny Chang-Claude in
Google Scholar
PubMed
Search for other papers by Rebecca Hein in
Google Scholar
PubMed
Search for other papers by Stefan Nickels in
Google Scholar
PubMed
Search for other papers by Shan Wang-Gohrke in
Google Scholar
PubMed
Search for other papers by Marc T Goodman in
Google Scholar
PubMed
Search for other papers by Michael E Carney in
Google Scholar
PubMed
Search for other papers by Rayna K Matsuno in
Google Scholar
PubMed
Search for other papers by Galina Lurie in
Google Scholar
PubMed
Search for other papers by Kirsten Moysich in
Google Scholar
PubMed
Queensland Institute of Medical Research, School of Public Health, Department of Preventive Medicine, Department of Epidemiology and Biostatistics, Program in Epidemiology, Obstetrics and Gynecology Epidemiology Center, Peter MacCallum Cancer Centre, Department of Epidemiology and Public Health, Cancer Epidemiology Program, Division of Cancer Epidemiology, Department of Obstetrics and Gynecology, Department of Biomedical Sciences, Department of Obstetrics and Gynecology, Roswell Park Cancer Center, Virus, Gynecologic Clinic, Department of Health Sciences Research, Department of Community and Family Medicine, Robert Wood Johnson Medical School, School of Public Health, National Cancer Institute, Division of Genetics and Epidemiology, Department of Cancer Epidemiology and Prevention, Department of Epidemiology, Department of Gynaecological Oncology, Royal Brisbane Hospital, Locked Bag 2000, Brisbane, Queensland 4029, Australia
Search for other papers by Susanne K Kjaer in
Google Scholar
PubMed
Search for other papers by Allan Jensen in
Google Scholar
PubMed
Search for other papers by Estrid Hogdall in
Google Scholar
PubMed
Search for other papers by Ellen L Goode in
Google Scholar
PubMed
Search for other papers by Brooke L Fridley in
Google Scholar
PubMed
Search for other papers by Robert A Vierkant in
Google Scholar
PubMed
Search for other papers by Melissa C Larson in
Google Scholar
PubMed
Search for other papers by Joellen Schildkraut in
Google Scholar
PubMed
Search for other papers by Cathrine Hoyo in
Google Scholar
PubMed
Search for other papers by Patricia Moorman in
Google Scholar
PubMed
Search for other papers by Rachel P Weber in
Google Scholar
PubMed
Search for other papers by Daniel W Cramer in
Google Scholar
PubMed
Search for other papers by Allison F Vitonis in
Google Scholar
PubMed
Search for other papers by Elisa V Bandera in
Google Scholar
PubMed
Search for other papers by Sara H Olson in
Google Scholar
PubMed
Search for other papers by Lorna Rodriguez-Rodriguez in
Google Scholar
PubMed
Search for other papers by Melony King in
Google Scholar
PubMed
Search for other papers by Louise A Brinton in
Google Scholar
PubMed
Search for other papers by Hannah Yang in
Google Scholar
PubMed
Search for other papers by Montserrat Garcia-Closas in
Google Scholar
PubMed
Search for other papers by Jolanta Lissowska in
Google Scholar
PubMed
Search for other papers by Hoda Anton-Culver in
Google Scholar
PubMed
Search for other papers by Argyrios Ziogas in
Google Scholar
PubMed
Search for other papers by Simon A Gayther in
Google Scholar
PubMed
Search for other papers by Susan J Ramus in
Google Scholar
PubMed
Search for other papers by Usha Menon in
Google Scholar
PubMed
Search for other papers by Aleksandra Gentry-Maharaj in
Google Scholar
PubMed
Search for other papers by Penelope M Webb in
Google Scholar
PubMed
it is possible that misclassification in earlier studies might have masked differences between the histological subtypes. In particular, it is now recognised that low- and high-grade invasive serous cancers are distinct entities and that many cancers
Search for other papers by Meilin Zhang in
Google Scholar
PubMed
Search for other papers by Jian Song in
Google Scholar
PubMed
Search for other papers by Shigang Guo in
Google Scholar
PubMed
Search for other papers by Feng Jin in
Google Scholar
PubMed
Search for other papers by Ang Zheng in
Google Scholar
PubMed
treatment (16 weeks) CCCA a High risk was defined as patients with four or more positive pathologic axillary lymph nodes or one to three positive axillary lymph nodes and at least one of the following: tumor size ≥ 5 cm, histologic grade 3, or
Search for other papers by Luisella Righi in
Google Scholar
PubMed
Search for other papers by Marco Volante in
Google Scholar
PubMed
Search for other papers by Ida Rapa in
Google Scholar
PubMed
Search for other papers by Veronica Tavaglione in
Google Scholar
PubMed
Search for other papers by Frediano Inzani in
Google Scholar
PubMed
Search for other papers by Giuseppe Pelosi in
Google Scholar
PubMed
Search for other papers by Mauro Papotti in
Google Scholar
PubMed
Introduction The management of lung neuroendocrine tumors (NETs) mainly depends on both grade of differentiation (low-to-intermediate versus high-grade (HG)) and clinical stage at diagnosis (localized versus metastatic). Surgery is the treatment of
Search for other papers by Alexa Childs in
Google Scholar
PubMed
Search for other papers by Amy Kirkwood in
Google Scholar
PubMed
Search for other papers by Julien Edeline in
Google Scholar
PubMed
Search for other papers by Tu Vinh Luong in
Google Scholar
PubMed
Search for other papers by Jennifer Watkins in
Google Scholar
PubMed
Search for other papers by Angela Lamarca in
Google Scholar
PubMed
Search for other papers by Doraid Alrifai in
Google Scholar
PubMed
Search for other papers by Phyllis Nsiah-Sarbeng in
Google Scholar
PubMed
Search for other papers by Roopinder Gillmore in
Google Scholar
PubMed
Search for other papers by Astrid Mayer in
Google Scholar
PubMed
UCL Cancer Institute, UCL, London, UK
Search for other papers by Christina Thirlwell in
Google Scholar
PubMed
Search for other papers by Debashis Sarker in
Google Scholar
PubMed
Search for other papers by Juan W Valle in
Google Scholar
PubMed
UCL Cancer Institute, UCL, London, UK
Search for other papers by Tim Meyer in
Google Scholar
PubMed
Introduction Neuroendocrine tumours (NETs) are exceptional in terms of their heterogeneity with respect to clinical behaviour and prognosis. Patients may live with low-grade, indolent tumours for 20years while the outlook for high-grade
Department of Biochemistry and Medical Genetics, Manitoba Institute of Cell Biology, Department of Structural and Cellular Biology, Manitoba Breast Tumour Bank, Tumour Tissue Repository and Deeley Research Centre, Faculty of Medicine
Search for other papers by Georgios P Skliris in
Google Scholar
PubMed
Search for other papers by Zoann J Nugent in
Google Scholar
PubMed
Search for other papers by Brian G Rowan in
Google Scholar
PubMed
Search for other papers by Carla R Penner in
Google Scholar
PubMed
Department of Biochemistry and Medical Genetics, Manitoba Institute of Cell Biology, Department of Structural and Cellular Biology, Manitoba Breast Tumour Bank, Tumour Tissue Repository and Deeley Research Centre, Faculty of Medicine
Department of Biochemistry and Medical Genetics, Manitoba Institute of Cell Biology, Department of Structural and Cellular Biology, Manitoba Breast Tumour Bank, Tumour Tissue Repository and Deeley Research Centre, Faculty of Medicine
Search for other papers by Peter H Watson in
Google Scholar
PubMed
Department of Biochemistry and Medical Genetics, Manitoba Institute of Cell Biology, Department of Structural and Cellular Biology, Manitoba Breast Tumour Bank, Tumour Tissue Repository and Deeley Research Centre, Faculty of Medicine
Search for other papers by Leigh C Murphy in
Google Scholar
PubMed
/421); PR-negative, 38% (160/421); low-grade, 28% (118/420); intermediate-grade, 62% (260/420); high-grade, 10% (42/420); tumour size <2.5 cm, 56% (237/422); tumour size >2.5 cm, 44% (185/422); age <50 years, 7% (31/420); age >50 years, 93% (389/420); node
Department of Anatomic Pathology Cleveland Clinic, Cleveland, Ohio 44195, USA
Department of Urology Stanford University School of Medicine, Stanford, California 94305, USA
Taussig Cancer Institute
Stanley Shalom Zielony Institute for Nursing Excellence Cleveland Clinic, Cleveland, Ohio 44195, USA
Department of Genetics and Genome Sciences
CASE Comprehensive Cancer Center Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USA
Search for other papers by Yu Wang in
Google Scholar
PubMed
Department of Anatomic Pathology Cleveland Clinic, Cleveland, Ohio 44195, USA
Department of Urology Stanford University School of Medicine, Stanford, California 94305, USA
Taussig Cancer Institute
Stanley Shalom Zielony Institute for Nursing Excellence Cleveland Clinic, Cleveland, Ohio 44195, USA
Department of Genetics and Genome Sciences
CASE Comprehensive Cancer Center Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USA
Search for other papers by Andres Roma in
Google Scholar
PubMed
Department of Anatomic Pathology Cleveland Clinic, Cleveland, Ohio 44195, USA
Department of Urology Stanford University School of Medicine, Stanford, California 94305, USA
Taussig Cancer Institute
Stanley Shalom Zielony Institute for Nursing Excellence Cleveland Clinic, Cleveland, Ohio 44195, USA
Department of Genetics and Genome Sciences
CASE Comprehensive Cancer Center Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USA
Search for other papers by Rosalie Nolley in
Google Scholar
PubMed
Department of Anatomic Pathology Cleveland Clinic, Cleveland, Ohio 44195, USA
Department of Urology Stanford University School of Medicine, Stanford, California 94305, USA
Taussig Cancer Institute
Stanley Shalom Zielony Institute for Nursing Excellence Cleveland Clinic, Cleveland, Ohio 44195, USA
Department of Genetics and Genome Sciences
CASE Comprehensive Cancer Center Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USA
Search for other papers by Fadi Abdul-Karim in
Google Scholar
PubMed
Department of Anatomic Pathology Cleveland Clinic, Cleveland, Ohio 44195, USA
Department of Urology Stanford University School of Medicine, Stanford, California 94305, USA
Taussig Cancer Institute
Stanley Shalom Zielony Institute for Nursing Excellence Cleveland Clinic, Cleveland, Ohio 44195, USA
Department of Genetics and Genome Sciences
CASE Comprehensive Cancer Center Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USA
Search for other papers by Donna M Peehl in
Google Scholar
PubMed
Department of Anatomic Pathology Cleveland Clinic, Cleveland, Ohio 44195, USA
Department of Urology Stanford University School of Medicine, Stanford, California 94305, USA
Taussig Cancer Institute
Stanley Shalom Zielony Institute for Nursing Excellence Cleveland Clinic, Cleveland, Ohio 44195, USA
Department of Genetics and Genome Sciences
CASE Comprehensive Cancer Center Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USA
Genomic Medicine Institute
Department of Anatomic Pathology Cleveland Clinic, Cleveland, Ohio 44195, USA
Department of Urology Stanford University School of Medicine, Stanford, California 94305, USA
Taussig Cancer Institute
Stanley Shalom Zielony Institute for Nursing Excellence Cleveland Clinic, Cleveland, Ohio 44195, USA
Department of Genetics and Genome Sciences
CASE Comprehensive Cancer Center Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USA
Genomic Medicine Institute
Department of Anatomic Pathology Cleveland Clinic, Cleveland, Ohio 44195, USA
Department of Urology Stanford University School of Medicine, Stanford, California 94305, USA
Taussig Cancer Institute
Stanley Shalom Zielony Institute for Nursing Excellence Cleveland Clinic, Cleveland, Ohio 44195, USA
Department of Genetics and Genome Sciences
CASE Comprehensive Cancer Center Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USA
Genomic Medicine Institute
Department of Anatomic Pathology Cleveland Clinic, Cleveland, Ohio 44195, USA
Department of Urology Stanford University School of Medicine, Stanford, California 94305, USA
Taussig Cancer Institute
Stanley Shalom Zielony Institute for Nursing Excellence Cleveland Clinic, Cleveland, Ohio 44195, USA
Department of Genetics and Genome Sciences
CASE Comprehensive Cancer Center Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USA
Genomic Medicine Institute
Department of Anatomic Pathology Cleveland Clinic, Cleveland, Ohio 44195, USA
Department of Urology Stanford University School of Medicine, Stanford, California 94305, USA
Taussig Cancer Institute
Stanley Shalom Zielony Institute for Nursing Excellence Cleveland Clinic, Cleveland, Ohio 44195, USA
Department of Genetics and Genome Sciences
CASE Comprehensive Cancer Center Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, USA
Search for other papers by Charis Eng in
Google Scholar
PubMed
to accurately predict oncologic outcomes for IRPC patients, especially for those with high Gleason grade lesions. Therefore, a reliable preoperative biomarker is urgently needed, which not only provides aggressive therapy for patients who will have
Search for other papers by Siker Kimbung in
Google Scholar
PubMed
Search for other papers by Ching-yi Chang in
Google Scholar
PubMed
Search for other papers by Pär-Ola Bendahl in
Google Scholar
PubMed
Search for other papers by Laura Dubois in
Google Scholar
PubMed
Duke Proteomics and Metabolomics Resource, Duke University School of Medicine, Durham, NC, USA
Search for other papers by J Will Thompson in
Google Scholar
PubMed
Search for other papers by Donald P McDonnell in
Google Scholar
PubMed
Clinical Trial Unit, Clinical Studies Sweden, Forum South, Skåne University Hospital, Lund, Sweden
Search for other papers by Signe Borgquist in
Google Scholar
PubMed
seen among high-grade tumors ( Nelson et al. 2013 ). In addition, the concentration of 27HC was found to be higher in ERα-positive breast tumors compared to normal breast tissue, and this was attributed to a corresponding decrease in the expression of
Search for other papers by Ivan Bièche in
Google Scholar
PubMed
INSERM,, University of Montpellier I,, INSERM,, Laboratoire d'Anatomo-Cytopathologie,, U844, Site Saint Eloi-Bat INM, 80, rue Augustin Fliche, Montpellier F-34091, France
Search for other papers by Carine Chavey in
Google Scholar
PubMed
Search for other papers by Catherine Andrieu in
Google Scholar
PubMed
INSERM,, University of Montpellier I,, INSERM,, Laboratoire d'Anatomo-Cytopathologie,, U844, Site Saint Eloi-Bat INM, 80, rue Augustin Fliche, Montpellier F-34091, France
Search for other papers by Muriel Busson in
Google Scholar
PubMed
Search for other papers by Sophie Vacher in
Google Scholar
PubMed
INSERM,, University of Montpellier I,, INSERM,, Laboratoire d'Anatomo-Cytopathologie,, U844, Site Saint Eloi-Bat INM, 80, rue Augustin Fliche, Montpellier F-34091, France
Search for other papers by Ludovic Le Corre in
Google Scholar
PubMed
Search for other papers by Jean-Marc Guinebretière in
Google Scholar
PubMed
INSERM,, University of Montpellier I,, INSERM,, Laboratoire d'Anatomo-Cytopathologie,, U844, Site Saint Eloi-Bat INM, 80, rue Augustin Fliche, Montpellier F-34091, France
Search for other papers by Sandrine Burlinchon in
Google Scholar
PubMed
Search for other papers by Rosette Lidereau in
Google Scholar
PubMed
INSERM,, University of Montpellier I,, INSERM,, Laboratoire d'Anatomo-Cytopathologie,, U844, Site Saint Eloi-Bat INM, 80, rue Augustin Fliche, Montpellier F-34091, France
Search for other papers by Gwendal Lazennec in
Google Scholar
PubMed
high expression of these chemokines involved gene regulation events and not gene amplification. We also observed that CXCL1, CXCL2, CXCL3, CXCL5, CXCL6 and CXCL8 chemokines were present at higher levels in metastases when compared with grade I and grade
Department of Urology, Research Center for Biosignal, Department of Clinical Pathology, CREST, Akita University Graduate School of Medicine, 1‐1‐1 Hondo, Akita 010-8543, Japan
Department of Urology, Research Center for Biosignal, Department of Clinical Pathology, CREST, Akita University Graduate School of Medicine, 1‐1‐1 Hondo, Akita 010-8543, Japan
Search for other papers by Mingguo Huang in
Google Scholar
PubMed
Department of Urology, Research Center for Biosignal, Department of Clinical Pathology, CREST, Akita University Graduate School of Medicine, 1‐1‐1 Hondo, Akita 010-8543, Japan
Search for other papers by Shintaro Narita in
Google Scholar
PubMed
Search for other papers by Takamitsu Inoue in
Google Scholar
PubMed
Department of Urology, Research Center for Biosignal, Department of Clinical Pathology, CREST, Akita University Graduate School of Medicine, 1‐1‐1 Hondo, Akita 010-8543, Japan
Search for other papers by Norihiko Tsuchiya in
Google Scholar
PubMed
Search for other papers by Shigeru Satoh in
Google Scholar
PubMed
Search for other papers by Hiroshi Nanjo in
Google Scholar
PubMed
Department of Urology, Research Center for Biosignal, Department of Clinical Pathology, CREST, Akita University Graduate School of Medicine, 1‐1‐1 Hondo, Akita 010-8543, Japan
Search for other papers by Takehiko Sasaki in
Google Scholar
PubMed
Department of Urology, Research Center for Biosignal, Department of Clinical Pathology, CREST, Akita University Graduate School of Medicine, 1‐1‐1 Hondo, Akita 010-8543, Japan
Search for other papers by Tomonori Habuchi in
Google Scholar
PubMed
). When the PCa patients were divided into three groups according to Gleason score (GS), serum MIC1 levels were significantly higher in patients with high-grade tumors than in patients with low-grade and moderate-grade tumors (ANOVA, P =0.013; high grade